• Article highlight
  • Article tables
  • Article images

Article History

Received : 11-07-2024

Accepted : 14-08-2024



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 217

PDF Downloaded: 73

Masud, Md. Sajedur Rahman, Jahan, Titas, Sany, Faysal, Sawon, and Md. Aoulad Hosen: Evaluation of multi-drug resistant isolates associated with clinical infections from two hospitals in the Dhaka region, Bangladesh


Introduction

Antibiotic resistance (ABR) represents a multifaceted global health crisis fueled by a complex interplay of factors, including overuse and misuse of antibiotics, inadequate healthcare infrastructure, and socio-economic disparities. While ABR poses a formidable challenge worldwide, its impact is particularly pronounced in low- and middle-income countries like Bangladesh. This introduction aims to provide a comprehensive overview of the ABR landscape in Bangladesh, drawing on existing literature to elucidate key drivers, challenges, and implications of antibiotic resistance in the country.

Bangladesh, a densely populated country in South Asia, grapples with many healthcare challenges, including limited access to quality healthcare services, widespread poverty, and inadequate sanitation infrastructure. Against this backdrop, the misuse and overuse of antibiotics have emerged as major contributors to the escalating burden of ABR. In resource-constrained settings, antibiotics are often prescribed indiscriminately, without proper diagnostic confirmation or adherence to treatment guidelines.1 Moreover, the availability of antibiotics without prescription, coupled with a lack of regulatory oversight, exacerbates the problem of antibiotic misuse among the general population.2

Studies conducted across various healthcare settings in Bangladesh have documented alarmingly high rates of antibiotic resistance among clinically significant pathogens. For instance, a study by3 reported widespread resistance to commonly used antibiotics such as ampicillin, ciprofloxacin, and co-trimoxazole among clinical isolates of Escherichia coli and Klebsiella pneumonia. Similarly, research conducted by4 highlighted the emergence of multidrug-resistant strains of Acinetobacter baumannii in hospital settings, posing significant challenges for infection control and patient management.

Despite the growing recognition of ABR as a public health threat, surveillance efforts in Bangladesh still need to be completed and adequate. As stated by Haque et al.,5 the absence of standardized surveillance protocols, limited laboratory capacity, and inadequate data-sharing mechanisms impede the timely detection and response to emerging resistance patterns. Furthermore, the need for coordination among stakeholders, including healthcare providers, policymakers, and researchers, hampers the development of comprehensive strategies to address ABR.6

The repercussions of antibiotic resistance extend beyond individual patient outcomes, encompassing broader socio-economic and public health implications. Treatment failures resulting from antibiotic resistance not only increase healthcare costs but also contribute to prolonged hospitalizations and higher mortality rates. 7 Moreover, the spread of resistant pathogens within healthcare facilities and communities amplifies the risk of outbreaks and undermines the effectiveness of infection control measures.8

In conclusion, Bangladesh's escalating threat of antibiotic resistance underscores the urgent need for concerted action to address this complex public health challenge. Efforts to combat ABR must encompass multifaceted interventions, including enhanced surveillance systems, rational antibiotic use policies, and investments in healthcare infrastructure. By adopting a comprehensive and collaborative approach, Bangladesh can mitigate the impact of antibiotic resistance and safeguard the health and well-being of its population.

Therefore, this study aims to isolate and identify multi-drug resistant isolates from various clinical samples collected in different hospitals in Dhaka, Bangladesh and to assess the multi-drug resistance profiles of the isolated bacteria.

Materials and Methods

Study design and period

The design followed in this research is a descriptive cross-sectional study. The study period of the research was from July 2022 to June 2023.

Sampling

A total of 100 human clinical samples were collected from Gonoshasthya Somajvittik Medical College Hospital (50) Savar and LABAID Hospital (50) Dhaka, Bangladesh. The clinical samples (blood, urine and pus) were collected from different age groups (11-74 years), including both male and female patients. Subsequently, all samples were properly labeled and transferred in an ice box to the laboratory of the Department of Microbiology, Gono Bishwabidyalay, for further processing and bacteriological analysis. The research commenced in December 2021 at the research laboratory of the Department of Microbiology, Gono Bishabidyalay, Dhaka, Bangladesh.

Isolation and identification of isolates

Samples were collected from clinically relevant areas, and data analysis was based on various parameters such as study period, location, clinical syndrome, age group, pathogen, susceptibility testing method, susceptibility testing standard, and source of infection. Bacterial isolation was performed using streaking principles, with subsequent identification based on colony morphology, Gram staining, and conventional biochemical tests.

The collected samples were processed according to.5 The specimens were cultured on Nutrient agar, Blood agar, MacConkey agar, EMB agar, SS agar, Cetrimide agar, Mannitol Salt Agar and Chromogenic agar, followed by overnight incubation at 37°C in an incubator (BIOBASE, China).

Gram staining

Gram staining was employed to morphologically differentiate bacteria based on cell wall constituents as primary identification. Crystal violet, Gram's iodine, ethanol or acetone, and safranin were utilized as stains. Gram-positive and Gram-negative bacteria were distinguished based on gram reactions.

Biochemical tests

Biochemical tests, including catalase, oxidase, coagulase, motility agar, urease, methyl red (MR), Voges-Proskauer (VP), and Triple Sugar Iron (TSI) tests were conducted for bacterial identification. Positive and negative reactions were interpreted based on specific colour changes or the presence of characteristic products. All media were purchased from HI Media Private Ltd., India. A loopful of each biochemically confirmed isolate was then inoculated into the nutrient broth containing 15% glycerol and frozen at -70˚C for further use. All media were purchased from HI Media Private Ltd., India.

Antibiotic sensitivity test

All biochemically identified isolates (n=146) were tested for their susceptibility to different antibiotics. In vitro antibiotic susceptibility testing was performed using the standardized agar disk diffusion method. Muller Hinton agar was employed, and the potencies of ten antibiotics were tested against various bacterial isolates. The tested antimicrobials discs were Azithromycin (15µg), Aztreonam (30µg), Amoxyclave (20µg), Cefixime (5µg), Ceftazidime(30µg), Ampiciline (10µg), Cefuroxime (30µg), Ciprofloxacin (5µg), Cotrimoxazol (25µg), and Gentamycin (10µg). The antibiotic sensitivity test was determined according to Clinical and Laboratory Standard Institute (CLSI) guidelines for agar disk diffusion (CLSI, 2021). 9 A pure bacterial colony (0.1 ml) was spread on the Mueller-Hinton agar plate, and antibiotic discs were placed on the plates. Then, the plates were incubated at 37°C for 16 to 18 hours in a standard incubator (BIOBASE, china). After overnight incubation, the inhibition zones were measured using a millimetre scale according to 9 guidelines. All diLegends: LAH: LABAID Hospital, GSVMC: Gonoshasthya Somajvittik Medical College were purchased from HI Media Private Ltd., India. All tests were done three times for result accuracy.

Multidrug Resistance (MDR) Strains Identification

Multi-drug resistance bacterial isolates were determined by using the disc diffusion method, according to. 10 Multi-drug resistance (MDR) was taken as resistant to four or more antibiotics tested.

Multiple Antibiotic Resistance (MAR) index determination

According to, the Multiple Antibiotic Resistance (MAR) index for each strain was determined, which,

MAR index= No. of resistance isolates / Total number of tested antibiotics

MAR index= A/B Where,

No of resistance isolates

B=Total number of tested antibiotics;

Statistical analysis

Statistical analysis was done based on data variables of isolates. All data were inputted on an Excel sheet, and then Excel version 21(different formulation) was applied for data analysis.

Ethical Approval

The ethical approval of the current research was taken from the hospital administrative office.

Figure 1

Frequency distribution of isolates in human clinical samples

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/8cd10a88-8bab-4ea9-a25a-fd60d77e9832image1.png
Figure 2

Frequency distribution of isolates in blood samplesbased on age group 1: E.coli, 2: Klebsiella spp., 3: Salmonella spp., 4: Pseudomonasspp., 5: Staphylococcus spp., 6: Candidaspp.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/8cd10a88-8bab-4ea9-a25a-fd60d77e9832image2.png

Figure 3

Frequency distribution of isolates in urine samplesbased on age group

1: E.coli, 2: Klebsiella spp., 3: Salmonella spp., 4: Pseudomonasspp., 5: Staphylococcus spp., 6: Candidaspp.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/8cd10a88-8bab-4ea9-a25a-fd60d77e9832image3.png

Figure 4

Frequency distribution of isolates in pus sample based on age group

1: E.coli, 2: Klebsiella spp., 3: Salmonella spp., 4: Pseudomonasspp., 5: Staphylococcus spp., 6: Candidaspp.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/8cd10a88-8bab-4ea9-a25a-fd60d77e9832image4.png

Table 1

Association of isolates with patient’s demographic characteristic (Gender, Age Group, Sampling type and area)

Variables

Number of examined

Total positive case (n=55) No (%)

Total isolates (n=146) No %

Gender (Sex)

Male

50

25

45.45

55

37.67

Female

50

30

54.55

91

62.33

Age group/year

11 to 30

50

20

36.36

52

35.62

31 to 60

25

18

32.73

54

36.99

61 to 74

25

17

30.91

40

27.40

Type of sample

Blood

40

10

18.18

32

21.92

Urine

40

25

45.45

79

54.11

Pus

20

15

27.27

35

23.97

Sampling area

GSVMC

50

30

54.55

82

56.16

LAH

50

25

45.45

64

43.84

[i] Legends: LAH: LABAID Hospital, GSVMC: Gonoshasthya Somajvittik Medical College

Table 2

Frequency distribution of isolates with patient samples (Blood, Urine and Pus)

Sample

Isolates

E. coli

Klebsiella spp.

Pseudomonas spp.

Salmonella spp.

Staphylococcus spp.

Candida spp.

Total

Blood

12 (22.64%)

6 (16.67%)

2 (100%)

1 (100%)

11 (40.74%)

0 (0%)

32 (21.91%)

Urine

28 (52.83%)

24 (66.67%)

0 (0%)

0 (0%)

0 (0%)

27 (100%)

79 (54.49%)

Pus

13 (24.52%)

6 (16.67%)

0 (0%)

0 (0%)

16 (59.26%)

0 (0%)

35 (23.97%)

Total

53

36

2

1

27

27

146

Table 3

Antibiotic Resistance profile of Multidrug-resistantE. coli from different sources

SL No.

Sources of Sample

Sampling location

Resistance Profile

No. of antibiotics to which isolates were resistant (a)

No. of antibiotics to which isolates were used (b)

MAR Index

1

Blood

LAH

AZM, ATM, AMC, CIP, AM, CXM, CFM, CAZ

8

10

0.8

2

Blood

LAH

AZM, ATM, AMC, CIP, CXM, CFM

6

10

0.6

3

Blood

GSVMC

AZM, ATM, AMC, CXM

4

10

0.4

4

Blood

GSVMC

AZM, ATM, CIP, AM

4

10

0.4

5

Urine

GSVMC

AZM, ATM, AM, CFM,

4

10

0.4

6

Urine

LAH

AZM, ATM, CIP

3

10

0.3

7

Urine

LAH

AZM, ATM, CIP

3

10

0.3

8

Urine

LAH

AZM, ATM, AMC, CIP

4

10

0.4

9

Urine

GSVMC

AZM, ATM, AMC, CIP

4

10

0.4

10

Urine

GSVMC

AZM, ATM, AMC

3

10

0.3

11

Urine

GSVMC

AZM, ATM, AMC

3

10

0.3

12

Urine

GSVMC

AZM, ATM, AMC

3

10

0.3

13

Urine

GSVMC

AZM, ATM, CIP, CFM

4

10

0.4

14

Pus

GSVMC

AZM, ATM, AMC, CIP, CFM

5

10

0.5

15

Pus

GSVMC

AZM, ATM, AMC, AM, CFM

5

10

0.5

16

Pus

GSVMC

AZM, ATM, AMC, CIP, CFM

5

10

0.5

17

Pus

GSVMC

AZM, ATM, AMC, CIP, AM

5

10

0.5

18

Pus

LAH

AZM, AMC, AM, CXM

4

10

0.4

19

Pus

LAH

AZM, ATM, AMC, CXM

4

10

0.4

20

Pus

LAH

AZM, CXM, AMC, CFM, CAZ

5

10

0.5

[i] Legends: AZM: Azithromycin, ATM: Aztreonam, AMC: Amoxyclav, CFM: Cefixime, CAZ: Ceftazidime, AM: Ampicillin, CXM: Cefuroxime, CIP: Ciprofloxacin.

[ii] LAH = LABAID Hospital, GSVMC: Gonoshasthya Somajvittik Medical College

Table 4

Antibiotic resistance profile of multidrug-resistantStaphylococcus spp. from different sources

SL No.

Sources of sample

Sampling location

Resistance Profile

No. of antibiotics to which isolates were resistant (a)

No. of antibiotics to which isolates were used (b)

MAR Index = a/b

1

Blood

LAH

TE, E, CIP, DA, CN, CF, COT, P

8

12

0.67

2

Blood

LAH

TE, E, CN, CF, COT, P

6

12

0.50

3

Blood

GSVMC

TE, E, DA, CF, COT, P

6

12

0.50

4

Blood

GSVMC

TE, CIP, CF, COT, P

5

12

0.42

5

Blood

GSVMC

TE, E, DA, CF, COT, P

6

12

0.50

6

Pus

LAH

TE, E, CIP, CN, VA, CF, DOX, COT, P

9

12

0.75

7

Pus

LAH

TE, CIP, CN, CF, P

5

12

0.42

8

Pus

LAH

E, LEV, DA, CF, P

5

12

0.42

 9

Pus

GSVMC

TE, E, CIP, DA, CF, DOX, COT, P

8

12

0.67

10

Pus

GSVMC

TE, E, CIP, CN, CF, DOX, P

7

12

0.58

11

Pus

GSVMC

TE, DA, CF, COT, P

5

12

0.42

 12

Pus

GSVMC

TE, E, CIP, CN, CF, P

6

12

0.50

 13

Pus

GSVMC

TE, LEV, DA, VA, CF, COT, P

7

12

0.58

 14

Pus

GSVMC

TE, E, CIP, CN, CF, P

6

12

0.50

 15

Pus

GSVMC

E, CIP, DA, CN, CF, P

6

12

0.50

[i] Legends: TE:Tetracycline, E:Erythromycin, CIP:Ciprofloxacin, DA:Clindamycin, CN: Gentamicin, CF:Cystic fibrosis, COT:Co-trimoxazole, P:Penicillin, VA:Vancomycin, DOX: Doxycycline, LEV:Levofloxacin, LAH = LABAID Hospital, GSVMC: Gonoshasthya Somajvittik Medical college.

Results

Association between frequency of isolates and patients

A total of 146 bacterial isolates were isolated and identified out of 55 positive cases from different sources. In this research, based on gender, a higher frequency of isolates was observed in females 91 (62.33%) whereas in males 55 (37.67%) respectively (Table 1). Regarding the age of patients, the result revealed that the highest number of isolates found in the 31-60 years age group, with 54 (36.99%) and 40 (27.40%), were found in the age group 61-74 years, respectively. Concerning the type of clinical samples, a high frequency of isolates, 79 (54.11%) observed in urine compared to other samples (Table 1). According to the sampling area, 86 (56.16%) isolates were identified in Gonosastho Hospital compared to Lab Aid Hospital 64 (43.84%) which was presented in (Table 1).

Frequency of isolates with blood, urine, and pus sample

In this study, out of 53 E. coli isolates, the highest number of isolates were recovered from urine sample 28 (52.83%), followed by pus sample 13 (24.52%) and blood sample 12 (22.64%) respectively, whereas Klebsiella spp. was measured 24 (66.67%) in urine and the least number found in blood and pus 6 (16.67%) (Table 2). Additionally, we recovered 27 (100%) Candida spp. In urine samples from female patients (Table 2).

According to our study, A total of 146 isolates were isolated and identified by different cultural and biochemical tests, including the highest prevalence of Gram-negative bacteria, 92 (64%), whereas Gram-positive bacteria, 27 (18%) and fungal strain 27(18%), respectively (Figure 1). In a blood sample, we recovered 32 isolates with the highest number of E. coli obtained 7/12 (58.33%) in the age group 31-60 years, Staphylococcus spp. 6/11 (54.54%) in the age group 31-60 years, Klebsiella spp. found 3/6 (50%) in the age group 11-30 years, whereas no Candida spp. was found (Figure 2). Consequently, in urine samples, 79 bacterial strains were recovered where 10/28 (35.71%) E. coli were found in age group 31-60 years and 61-74 years, 9/24 (37.50%) Klebsiella spp. in 61-74 years, 10/27 (37.03%) Candida spp. found in the age group 11-30 years and 9/27 (33.33%) in age 61-74 years respectively (Figure 3). In this research, a total of 35 isolates were obtained from pus samples, including the highest 7/16 (43.75%) Staphylococcus spp. in the age group 11-30 years, 5/13 (38.46%) E. coli in the age group 11-30 years and 31-60 years respectively (Figure 4).

Antibiotic resistance pattern and MAR index calculation

In the present study, out of 146 isolates, 35 (24%) multi-drug resistant bacteria were found. According to the results, 20/146 (14%) multi-drug resistances E. coli were identified, and resistance profiles were shown on different commercial antibiotics. E. coli demonstrated high resistance toward azithromycin 20 (100%), followed by aztreonam 18 (90%), amoxiclav 15 (75%), and ciprofloxacin 11 (55%) compared to other commercial antibiotics (Table 3). Notably, this research measured the least resistance profile of ceftazidime 2 (10%) in blood and pus samples from Lab Aid Hospital. Based on CLSI interpretation criteria, 37.73% (20/53) of multidrug-resistant E. coli were mentioned in this study. Consequently, 45% (9/20) of multidrug-resistant E. coli were found in the urine sample, followed by 35% (7/20) in the pus sample and 20% (4/20) in the blood sample, respectively. Table 3 represents the MAR index calculation of isolated multi-drug resistance E. coli from different sources. In tabLegends: LAH: LABAID Hospital, GSVMC: Gonoshasthya Somajvittik Medical College 3, the MAR index ranged from 0.3 to 0.8, and the average MAR index was 0.43. Additionally, the highest number of antibiotics showed resistance (MAR index 0.8) in blood samples from Lab Aid Hospital, Dhaka, compared to other samples as well as another hospital.

According to the obtained results, out of 27 Staphylococcus spp. isolates, 15 multi-drug rLegends: LAH: LABAID Hospital, GSVMC: Gonoshasthya Somajvittik Medical college resistance Staphylococcus spp. were identified and showed resistance profile on different commercial antibiotics. Staphylococcus spp. showed high resistance to penicillin-G and cefixiLegends: LAH: LABAID Hospital, GSVMC: Gonoshasthya Somajvittik Medical College 15 (100%), followed by tetracycline 13 (86.67%), erythromycin 11 (73.33%), ciprofloxacin and cotrimoxazole 9 (60%) compared to other commercial antibiotics (Table 4). Notably, in this research, the least resistance profile of vancomycin 1 (6.67%) was measured in pLegends: LAH: LABAID Hospital, GSVMC: Gonoshasthya Somajvittik Medical collegeus sample from Gonosastho Hospital. Based on CLSI interpretation criteria, 55.55% (15/27) multi-drug resistance Staphylococcus spp. were mentioned in this study. Consequently, 66.67% (10/15) of multidrug-resistant Staphylococcus spp. were found in pus samples, followed by 33.33% (5/15) in blood samples, respectively. Table 4 represents the MAR index calculation of isolated multi-drug resistance Staphylococcus spp. from different sources, whereas the MAR index ranged from 0.42 to 0.75, and the average MAR index was 0.52. Additionally, the highest number of antibiotics showed resistance (MAR index 0.75) in the pus sample from Lab Aid Hospital, Dhaka, compared to other samples as well as another hospital.

Discussion

The escalating issue of multi-drug resistance (MDR) in bacteria poses a significant challenge for clinicians, given the ability of these microorganisms to develop resistance to multiple antibiotics. This resistance not only results in a financial burden and increased treatment failures but also facilitates the rapid spread of infections from person to person. Over the past fifty years, the pervasive use of antibiotics has contributed to the emergence of non-fermentative Gram-negative bacteria as critical healthcare-associated pathogens. Consequently, recent studies have concentrated on identifying these bacteria and monitoring their susceptibility patterns to improve infection management strategies. Establishing the clinical relevance of isolated non-fermentative Gram-negative bacilli is crucial before classifying them as pathogens, which can prevent unnecessary antibiotic usage and the rise of drug-resistant strains.

Our study addresses the limited data on the prevalence of MDR E. coli and Staphylococcus spp., highlighting their isolation from diverse clinical samples (blood, urine, and pus) in suspected patients aged 11-74 years. The highest number of MDR E. coli isolates was observed in the 31-60 age group, followed by the 11-60 and 61-74 years groups. Similarly, MDR Staphylococcus spp. Showed the highest prevalence in the 31-60 years age group. Gender-wise distribution revealed a higher incidence of MDR isolates in females (62.33%); these findings align with previous studies by Muhammad Zahid 11, where the occurrence was lower in males (47%, n= 324) as compared to females (53%, n = 324). This trend may be attributed to social and cultural factors in developing countries like Bangladesh, where females often face neglect, leading to poorer food hygiene and weaker immune systems. Additionally, frequent hospital admissions due to childbirth increase their exposure to infections.

In our study, we identified 79 bacterial strains, with notable findings such as 35.71% of E. coli (10/28) occurring predominantly in the age groups of 31-60 years and 61-74 years, 37.50% of Klebsiella spp. (9/24) in the 61-74 age group, and 37.03% of Candida spp. (10/27). These results closely align with those reported by Mohammad Aminul Islam 12, who observed E. coli (51.6%) as the primary pathogen, followed by Streptococcus spp. (15.7%) and Klebsiella spp. (12.1%) in individuals aged ≥18 years.

In the present study, out of 146 isolates, 35 (24%) were identified as multidrug-resistant bacteria. This percentage is considerably lower than the findings of Meng Wang 13, who reported that among 7579 bacterial isolates from patients with healthcare-associated infections (HAI), 3223 (42.5%) were multidrug-resistant. According to this study, 20 out of 146 (14%) isolates were identified as multidrug-resistant E. coli, exhibiting resistance to various commercial antibiotics. In contrast, S. Shakya14 found a significantly higher prevalence of multidrug-resistant E. coli in their study, with 1000 out of 1865 (54%) isolates showing resistance to commonly used antibiotics for urinary tract infections (UTIs).

Based on CLSI interpretation criteria, 55.55% (15/27) of Staphylococcus spp. isolates in this study were identified as multidrug-resistant. Specifically, 66.67% (10/15) of these multidrug-resistant Staphylococcus spp. were found in pus samples, and 33.33% (5/15) were in blood samples. All Staphylococcus spp. isolates showed high resistance to penicillin-G and cefixitin (100%). This study can be compared to the findings of Prashant Adhikari 15, where among 7433 clinical samples analyzed, Staphylococcus aureus was recovered from 499 (6.71%), with a prevalence of MRSA at 26.4% (95% CI 21.6% to 30.4%). The major source of MRSA was pus, accounting for 71 (18.5%) of the cases.

Limitations and future researh

Several limitations warrant consideration, including the study's retrospective design and potential biases in patient selection and sample collection. Future research should focus on prospective studies with larger sample sizes to validate these findings across different healthcare settings. Additionally, molecular techniques could provide insights into genetic determinants of resistance, aiding in targeted therapeutic approaches.

Conclusion

The presence of MDR E. coli and Staphylococcus spp. in clinical samples, including blood, urine, and pus, highlights a severe public health concern in Bangladesh, particularly due to the potential transmission of these pathogens through food and water. The study's findings underscore that MDR isolates, especially prevalent in the 31-60-year-old age group, pose significant challenges to infection prevention, given the possible impact on immunity in this demographic. The rising threat of MDR bacteria necessitates the urgent discovery of new effective antibiotics to safeguard human health and the environment. Bangladesh's healthcare system and global health settings must prioritize surveillance of drug resistance in microorganisms, particularly in clinical sectors. Public health awareness campaigns should focus on the prudent use of antibiotics and emphasize preventive measures prescribed by health professionals. By fostering a comprehensive understanding of antibiotic resistance and promoting responsible antibiotic usage, we can mitigate the spread of MDR bacteria and protect public health.

Source of Funding

None.

Conflict of Interest

None.

Acknowledgments

The authors want to special thanks to Gonosastho Samajvittik Medical College Hospital and LABAID Hospital for their valuable support during the collection of samples. The authors also want to give special thanks to the Department of Microbiology, Gono Bishwabidyalay, for providing their Laboratory facilities.

References

1 

S Sarker A Nahar Antimicrobial susceptibility pattern of pathogenic bacteria in a tertiary care hospital in Dhaka, BangladeshBangladesh J Infect Dis201851610

2 

AK Sinha A Banik Antibiotic resistance pattern of clinical isolates of Escherichia coli in a tertiary care hospital in Dhaka CityJ Inf P Health20181122412

3 

MR Hasan M Rahman MM Hasan Antibiotic resistance patterns of Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in a tertiary care hospital of BangladeshInt J Inf Dis20191115618

4 

A Hossain RR Das MS Islam Antimicrobial resistance patterns of Acinetobacter baumannii in a tertiary care hospital in DhakaJ Inf in Dev Count20201444004

5 

A Haque MA Rahman MM Molla Antibiotic resistance of Escherichia coli isolated from food and clinical environment in China from 2001 to 2020Sci Total Environ201810173498Bangladesh. Cureus

6 

S Islam B Hossain M Rahman Antibiotic resistance pattern of bacterial isolates in intensive care unit of tertiary care hospital in BangladeshJ Inf Pub Health201912123

7 

M Rahman M Haque Prevalence of multidrug-resistant bacterial pathogens in a tertiary care hospital in DhakaJ Inf Dev Count2017364916

8 

M Rahman M Haque S Islam Bacterial profile and antimicrobial susceptibility pattern of blood culture isolates among septicemia patients in DhakaJ Inf and Pub Health2019171115

9 

CLSI supplement M100). Clinical and Laboratory Standards Institute2021https://clsi.org/media/1469/m100s27_sample.pdf

10 

CN Ezekiel AO Olarinmoye J Oyinloye Distribution, antibiogram and multidrug resistance in Enterobacteriaceae from commercial poultry feeds in NigeriaAfr J Microb Res201153294301

11 

M Zahid M Akbar AA Sthanadar Isolation and identification of multi-drug resistant strains of non-lactose fermenting bacteria from clinical refuse in major hospitals of Khyber Pakhtunkhwa, PakistanJ Med Microb201442766891

12 

MA Islam MR Islam R Khan Prevalence, etiology and antibiotic resistance patterns of community-acquired urinary tract infections inPLoS One2022179e0274423

13 

M Wang H Wei Y Zhao Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in ChinaBosnian J B Med Sci20191918693

14 

S Shakya J Edwards HA Gupte High multidrug resistance in urinary tract infections in a tertiary hospitalPub Health Action20211112431

15 

P Adhikari D Basyal JR Rai Prevalence, antimicrobial susceptibility pattern and multidrug resistance of methicillin-resistant Staphylococcus aureus isolated from clinical samples at a tertiary care teaching hospital: an observational, cross-sectional study from the Himalayan countryBMJ Open2023135e067384



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International, which allows others to remix, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.